Discover and read the best of Twitter Threads about #Aurobindopharma
Most recents (5)
Stocks which made 52 week high today (1/n):
#AaPlus
#AbbIndia
#ActionConst
#AdorFontech
#AiaEngineering
#AnantRaj
#AndhraRaj
#AndhraCement
#ArmanFinancial
#ArmanHoldings
#Stockmarket
#AaPlus
#AbbIndia
#ActionConst
#AdorFontech
#AiaEngineering
#AnantRaj
#AndhraRaj
#AndhraCement
#ArmanFinancial
#ArmanHoldings
#Stockmarket
Stocks which made 52 week high today (2/n):
#ArrowGreentech
#Arvind
#AurobindoPharma
#AvanceTech
#BajajHoldings
#BampslSec
#BccFuba
#BerylSecuritie
#BhansaliEng
#BharatWireRop
#BhartiAirtel
#StockMarket
#ArrowGreentech
#Arvind
#AurobindoPharma
#AvanceTech
#BajajHoldings
#BampslSec
#BccFuba
#BerylSecuritie
#BhansaliEng
#BharatWireRop
#BhartiAirtel
#StockMarket
Stocks which made 52 week high today (3/n):
#BselInfra
#CanfinHomes
#CclProducts
#CgPower
#ChoiceInternat
#CianHealthcare
#CoforgeLtd
#Comfort
#Craftman
#CredirAccessGr
#CRISIL
#DeshRAKSHAK
#StockMarket
#BselInfra
#CanfinHomes
#CclProducts
#CgPower
#ChoiceInternat
#CianHealthcare
#CoforgeLtd
#Comfort
#Craftman
#CredirAccessGr
#CRISIL
#DeshRAKSHAK
#StockMarket
#AurobindoPharma Q3 FY22 concall highlights 💊💊
Like & retweet for better reach !
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
Like & retweet for better reach !
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
Aurobindo CMP 868
The company is developing:
✍️14 Biosimilars (5 of these expected to launch by FY25 with a US$20 market size)
✍️8 inhalers (US market size is >$10 Bn)
✍️Pneumcoccal Conjugate Vaccine (US$6.2 bn global market size)
✍️3 depot injectables (US$3.3 bn market size)
The company is developing:
✍️14 Biosimilars (5 of these expected to launch by FY25 with a US$20 market size)
✍️8 inhalers (US market size is >$10 Bn)
✍️Pneumcoccal Conjugate Vaccine (US$6.2 bn global market size)
✍️3 depot injectables (US$3.3 bn market size)
Co also developing 50 Other Complex generics
✍️Peptides (US$14.5 Bn Mkt size-Global $2.5 bn size for 5 filed ANDAs and Global $12bn for 10 under development)
✍️Topicals (US$4 Bn Mkt size-26 products under development currently out of total 37 products identified for development)
✍️Peptides (US$14.5 Bn Mkt size-Global $2.5 bn size for 5 filed ANDAs and Global $12bn for 10 under development)
✍️Topicals (US$4 Bn Mkt size-26 products under development currently out of total 37 products identified for development)
✍️Transdermal patches (US$3 Bn Global Mkt size) : 8 products under development (Clinical trials to begin for the 1st product in FY21)
✍️Nasals (US$1.3 Bn Mkt size) : 1 approved + 4 under development (Filing will be done over the course of next 3 yrs)
#Aurobindopharma
#Growth
✍️Nasals (US$1.3 Bn Mkt size) : 1 approved + 4 under development (Filing will be done over the course of next 3 yrs)
#Aurobindopharma
#Growth
Trade With Channels: CAN THE RETAIL INVESTORS MAKE MONEY? 13TH AUGUST B... tradewithchannels.blogspot.com/2020/08/can-re…
- Pharma MNCs riding on innovation & operating in niche therapies (less competition), focus on few brand & enjoy premium pricing, 100% focus on India market.
- Indian cos; struggle with regulatory hurdles (US FDA), 70% revenue from overseas biz, currency & geopolitical risks.
- Indian cos; struggle with regulatory hurdles (US FDA), 70% revenue from overseas biz, currency & geopolitical risks.
Indian pharma companies are facing a lot of compliance issues. If current situation continues, they might not get approval of pending products which ultimately impact on topline of these companies
#Lupin
#AurobindoPharma
#Cipla
@caniravkaria @_N_U_P_K_Y
#Lupin
#AurobindoPharma
#Cipla
@caniravkaria @_N_U_P_K_Y
Pfizer Q2 sales 567crs vs 519 crs, net profits up 60% at 154 crs vs 96
As mentioned, Pharma MNCs are exceedingly doing well compared to Indian pharma players!!
#Pfizer
#Abbott
#Merck
#Sanofi
#Glaxosmith
As mentioned, Pharma MNCs are exceedingly doing well compared to Indian pharma players!!
#Pfizer
#Abbott
#Merck
#Sanofi
#Glaxosmith
